Yazar "Kıskaç, Muharrem" için listeleme
-
Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients
Çakırca, Mustafa; Karatoprak, Cumali; Zorlu, Mehmet; Kıskaç, Muharrem; Kanat, Mustafa; Çıkrıkçıoğlu, Mehmet Ali; Soysal, Pınar; Hurşitoğlu, Mehmet; Çamlı, Ahmet Adil; Erkoç, Reha; Abdul-Ghani, Muhammad (Dove Medical Press, 2014)Aims: A close association has been demonstrated between increased cardiovascular risk and high asymmetric dimethylarginine (ADMA) levels in type 2 diabetes mellitus (DM) patients. We planned to measure serum ADMA levels ... -
Evaluation of the relationship between vitamin D level and adropin, IL-1β, IL-6, and oxidative status in women
Zorlu, Mehmet; Şekerci, Abdüsselam; Tunç, Muhammed; Güler, Eray Metin; Gülen, Bedia; Karatoprak, Cumali; Kıskaç, Muharrem; Çakırca, Mustafa (Turkiye Klinikleri, 2022)Background/aim: Vitamin D, adropin, proinflammatory cytokines, and oxidative stress closely related with metabolic homeostasis and endothelial dysfunction. The aim of the present study is to investigate how vitamin D levels ... -
GAS6 intron 8 c.834+7G > A gene polymorphism in diabetic nephropathy
Erkoç, Reha; Çıkrıkçıoğlu, Mehmet Ali; Aintab, Emre; Erek-Toprak, Aybala; Kılıç, Ülkan; Gök, Özlem; Yasin Çetin, Ayşe İrem; Zorlu, Mehmet; Kıskaç, Muharrem; Çakırca, Mustafa; Erkal, Sena Nur; İsen, Hayati Can; Karatoprak, Cumali (Taylor and Francis, 2015)Background - Aim: In animal experiments, growth arrest-specific 6 (Gas6) protein plays a key role in the development of mesangial cell and glomerular hypertrophy in the early phase of diabetic nephropathy, and diabetic ... -
Vildagliptin treatment on the portal venous pressure and hepatosteatosis in patients with type 2 diabetes mellitus
Karatoprak, Cumali; Kılıçarslan, Rukiye; Çakırca, Mustafa; Aydın, Sinem; Özkan, Tuba; Kocaman, Orhan; Yolbaş, Servet; Zorlu, Mehmet; Kıskaç, Muharrem; Çıkrıkçıoğlu, Mehmet Ali; Erkoç, Reha (AVES, 2018)Objective: ftis study investigated how vildagliptin (a di-pepti- dyl peptidase 4 inhibitor) affects portal vein pressure and hepat- osteatosis in patients with type 2 diabetes mellitus. Methods: ftis cross-sectional study ...